News
Gold Reserve Reports on Results of Annual Meeting
Gold Reserve Inc. (TSX.V: GRZ) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announced that, at the annual general meeting held earlier today, James H. Coleman, Rockne J. Timm, A. Douglas
Caledonia Mining mit Spitzenergebnis! EBITDA steigt um 30 %
Kaufkraft des Geldes schwindet – auf Gold und Silber setzen
Diversifizierung bei der Vermögensanlage
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November
SunOpta Announces Third Quarter Fiscal 2021 Financial Results
SunOpta Inc. (“SunOpta” or the “Company”) (Nasdaq:STKL) (TSX:SOY), a leading healthy food and beverage company focused on plant-based foods and beverages and fruit-based foods and beverages, today
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving
Silber und Lithium können zusammenwirken
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while
Ohne Gold und Silber geht es nicht
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are
Die eigene Mine giert schon fast nach Erz!
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated
Länder mit großen Gegensätzen, aber auch Rohstoffen und neuester Technologie
SunOpta Inc. Schedules Third Quarter 2021 Financial Results Release and Conference Call
SunOpta Inc. ("SunOpta") (Nasdaq:STKL) (TSX:SOY) announced today that it will issue financial results for the third quarter 2021 before the markets open on Wednesday, November 10, 2021.
Following
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021, before the markets open
Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that
Amerikaner könnten Goldfans werden
Rupert Resources Reports Results for 3 and 6 Months Ending August 31, 2021
Rupert Resources Ltd (“Rupert” or the “Company”) announces that it has published its unaudited, condensed consolidated interim financial statements for the three and six months ending August 31
Mit Edelmetallaktien der Inflation entgegenwirken
Endeavour Silver produziert auf Hochtouren! Jahresprognose nochmals erhöht!
Cholera und Corona sorgten für einen zweimaligen Ausfall des Oktoberfestes
Die globale Energiewende benötigt Rohstoffe
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the